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Fucosyltransferase 1 Mediates Angiogenesis in
Rheumatoid Arthritis
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Christine M. Ha,1 W. Alex Stinson,1 Steven E. Domino,1 and Alisa E. Koch2
Objective. To determine the role of (1,2)-linked
fucosylation of proteins by fucosyltransferase 1 (FUT1)
in rheumatoid arthritis (RA) angiogenesis.
Methods. Analysis of (1,2)-linked fucosylated
proteins in synovial tissue (ST) samples was performed
by immunohistologic staining. Expression of (1,2)-
linked fucosylated angiogenic chemokine in synovial
fluid (SF) was determined by immunoprecipitation and
lectin blotting. To determine the angiogenic role of
(1,2)-linked fucosylated proteins in RA, we performed
human dermal microvascular endothelial cell (HMVEC)
chemotaxis and Matrigel assays using sham-depleted
and (1,2)-linked fucosylated protein–depleted RA SF
samples. To examine the production of proangiogenic
chemokines by FUT1 in HMVECs, cells were transfected
with FUT1 sense or antisense oligonucleotides, and
enzyme-linked immunosorbent assay was performed.
We then studied mouse lung endothelial cell (EC)
chemotaxis using wild-type and FUT1 gene–deficient
mouse lung ECs.
Results. RA ST endothelial cells showed high
expression of (1,2)-linked fucosylated proteins com-
pared to normal ST. The expression of (1,2)-linked
fucosylated monocyte chemoattractant protein 1 (MCP-
1)/CCL2 was significantly elevated in RA SF compared
with osteoarthritis SF. Depletion of (1,2)-linked fuco-
sylated proteins in RA SF induced less HMVEC migra-
tion and tube formation than occurred in sham-depleted
RA SF. We found that blocking FUT1 expression in ECs
resulted in decreased MCP-1/CCL2 and RANTES/CCL5
production. Finally, we showed that FUT1 regulates EC
migration in response to vascular endothelial cell growth
factor.
Conclusion. Our findings indicate that (1,2)-
linked fucosylation by FUT1 may be an important new
target for angiogenic diseases such as RA.
Posttranslational protein modification can lead to
alteration of biologic properties of proteins (1,2). Gly-
cosylation is one of these modifications, and many
proteins are glycosylated in eukaryotes (3). For example,
oligosaccharide antigens are used as tumor markers, and
oligosaccharides in tumors modulate functions such as
tumor cell adhesion and invasion (4). It has also been
shown that the expression of sialyl-Lewisx is elevated in
gastric cancers, and several antibodies raised against
sialyl-Lewisx are used for the diagnosis of cancers (4).
Fucosylation of glycoproteins involves the biologic func-
tions of adhesion molecules and growth factor receptors
(5). Fucosylated glycans are synthesized by 13 fucosyl-
transferases (FUTs). Terminal fucose can be linked to
(1,2)-, (1,3)-, (1,4)-, or (1,6)-orientations by these
FUTs. In addition, expression of FUTs has been re-
ported in some cancers, such as prostate and pancreatic
cancer (6,7).
FUT1 and FUT2 are (1,2)-fucosyltransferases
responsible for synthesis of the H blood group antigen
(8,9). The expression of cancer-associated carbohydrate
antigens is modified by abnormal control by glycosyl-
transferases. We have previously shown that the soluble
form of E-selectin mediates angiogenesis via its endo-
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thelial ligand sialyl-Lewisx (10), and that a related anti-
gen, Lewisy-6/H/5-2 (Ley/H), which is synthesized by
FUT1, and its glucose analog 2-fucosyllactose, mediate
angiogenesis and inflammatory cell adhesion (11,12).
Progression of rheumatoid arthritis (RA) is char-
acterized by the appearance of inflammatory cells in
both the pannus and joint fluid and by eventual tissue
destruction. The RA synovium contains elevated levels
of proangiogenic cytokines and inflammatory cells, such
as lymphocytes and monocytes (13,14). One of the most
effective current therapies is designed to block tumor
necrosis factor  (TNF) (15). Some TNF-blocking
biologic agents are composed of IgG, and glycosylation
in the Fc region plays an important role in the stability
and effectiveness of such therapeutics (16).
Angiogenesis is critical in vasculoproliferative
processes, including tumor growth, and inflammatory
states such as psoriasis and RA (17). The process of
angiogenesis contributes to RA progression and may be
an appropriate therapeutic target (18). In this study, we
demonstrate the expression of (1,2)-linked fucosylated
proteins in RA and their role in angiogenesis and cell
recruitment. We also show that blocking FUT1 in endo-
thelial cells (ECs) reduces production of proangiogenic
chemokines and EC migration.
MATERIALS AND METHODS
Patients. RA and osteoarthritis (OA) synovial tissue
(ST) samples were obtained from patients undergoing arthro-
plasty or synovectomy. Normal ST samples were obtained from
a National Disease Research Interchange and Cooperative
Human Tissue Network. RA and OA synovial fluid (SF)
samples were obtained from the patients. Normal skin tissue
samples were obtained from the University of Michigan Tissue
Procurement Service. All specimens were collected following
approval by the University of Michigan Institutional Review
Board.
Generation of FUT1 gene–deficient mice. FUT1 gene–
deficient mice have been generated previously (19–21). Mice
were viable without gross defects, and were bred onto a
C57BL/6 background (19–21). FUT1 gene–deficient mice
were later obtained from the Consortium for Functional
Glycomics. C57BL/6 wild-type mice were bred in-house or
purchased from the National Cancer Institute. All animal
experiments were approved by the University of Michigan
Committee on Use and Care of Animals.
Cell culture. Human dermal microvascular endothelial
cells (HMVECs) were purified from digested skin tissue
specimens using mouse anti-human CD31 MicroBeads accord-
ing to the recommendations of the manufacturer (Miltenyi
Biotec). Cells were cultured in EC basal medium (Lonza) with
all growth factors. In order to confirm EC purification, we
examined EC markers on these cells using antibodies to von
Willebrand factor (vWF) and CD31.
Isolation and confirmation of EC purity in mouse lung
preparations. Mouse lung ECs were harvested from wild-type
and FUT1 gene–deficient mouse lungs using rat anti-mouse
CD146 MicroBeads according to the recommendations of the
manufacturer (Miltenyi Biotec), and cultured in EC basal
medium with all growth factors (Lonza) (22).
Flow cytometry. In order to confirm mouse lung EC
purity, we performed flow cytometry using fluorescein isothio-
cyanate (FITC)–conjugated CD146 antibody (Miltenyi Bio-
tec). Mouse lung ECs (3  106 cells/ml) were suspended in
blocking buffer and incubated for 15 minutes at 4°C. The cells
were incubated with rat FITC-conjugated IgG or FITC-
conjugated CD146 for 30 minutes at 4°C. Flow cytometry was
performed as previously described (23).
Cell treatment. HMVECs and mouse lung ECs were
seeded in 6-well plates (BD Biosciences) at a density of 2 105
cells per well. Cells were then maintained in EC basal medium
with 5% fetal bovine serum (FBS). After overnight serum
starvation, cells were treated with TNF (25 ng/ml; R&D
Systems) for various time periods or interleukin-1 (IL-1) (25
ng/ml; R&D Systems) as previously described (24,25). Cell-
conditioned medium was collected and used in assays.
Immunofluorescence staining. Immunofluorescence
staining was performed as previously described (26). To deter-
mine if (1,2)-linked fucosylated proteins were expressed on
RA, OA, and normal ST ECs, rabbit anti-human vWF (Dako)
and goat anti–Ulex europaeus agglutinin type I (anti–UEA-I;
Vector) were used. RA, OA, and normal ST slides were fixed
with cold acetone for 20 minutes. Then slides were blocked
with 20% FBS and 5% donkey serum for 1 hour at 37°C, and
incubated with UEA-I (2 g/ml; Vector) for 1 hour at 37°C.
UEA-I binds specifically to (1,2)-fucose, the terminal sugar of
blood group antigens H and Lewisy. Goat anti–UEA-I and
rabbit anti-human vWF were used as primary antibodies.
Fluorescence-conjugated donkey anti-goat (for UEA-I) and
anti-rabbit (for vWF) secondary antibodies were purchased
from Life Technologies. DAPI was used for nuclear staining.
Images were obtained at 200 magnification. Anti-vWF–
positive vessels were shown by fluorescent green staining, and
fucosylation was shown by fluorescent red staining. Yellow
vessels were a result of the merger of the green and red fields.
We determined the percentage of (1,2)-fucosylated vessels in
RA, OA, and normal ST by counting the total number of
yellow vessels, and divided this value by the total number of
vessels (green) in each tissue section. Each section was evalu-
ated by an observer who was blinded with regard to the
experimental conditions.
Depletion of rheumatoid factor (RF) from SF. To
avoid any possible confounding effects of RF on assays, RF
was immunodepleted from SF samples using anti-IgM antibod-
ies coupled to agarose beads (Sigma-Aldrich) as previously
described (23). Removal of RF was determined by randomly
choosing 6 RA SF samples and measuring RF levels before
and after immunodepletion using an RF enzyme-linked immu-
nosorbent assay (ELISA) kit (Alpha Diagnostic). Before im-
munodepletion, RF levels were measured and ranged from 21
IU/ml to 132 IU/ml. After immunodepletion, all samples had
RF levels 10 IU/ml (data not shown).
Immunoprecipitation and lectin blotting. RF-depleted
RA SF and OA SF samples were incubated with mouse
anti-human monocyte chemoattractant protein 1 (MCP-1)/
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CCL2 antibody (R&D Systems) for 2 hours. The antibody–
protein complexes were incubated with protein A–agarose
beads (Millipore) overnight at 4°C. The next day, antibody–
protein–agarose bead complexes were washed 5 times with Tris
buffered saline (TBS; 50 mM Tris Cl [pH 7.6] and 150 mM
NaCl), and resuspended in Laemmli sample buffer.
For lectin blotting, samples were loaded onto two 10%
polyacrylamide gels under reducing conditions. One gel was
stained with Coomassie brilliant blue R250 (Bio-Rad). The
other gel was electrotransferred onto a PVDF membrane.
After transfer, the membrane was washed with TBS containing
0.05% Tween 20 (TBST), blocked with 2% bovine serum
albumin in TBST overnight at 4°C, and incubated with 5 g/ml
of biotinylated UEA-I (Vector) for 1 hour at room tempera-
ture. After washing with TBST, the blot was incubated with
streptavidin–horseradish peroxidase (HRP) diluted 1:50,000
(BD Biosciences) for 1 hour at room temperature. Finally, the
blot was washed with TBST and the color was developed using
a BCIP/NBT Liquid Substrate System (Sigma-Aldrich). As a
loading control, the blots were stripped and probed with an
anti–MCP-1/CCL2 antibody (R&D Systems). Densitometric
analysis of the bands was performed using Un-Scan-It soft-
ware, version 5.1 (Silk Scientific).
Neutralization of (1,2)-linked fucosylated proteins
in RA SF. To determine the role of (1,2)-linked fucosylated
proteins in RA SF, RA SF samples were depleted using
UEA-I–conjugated agarose beads (Vector). RA SF samples
(1:50 diluted with phosphate buffered saline [PBS]) were
mixed overnight with UEA-I–conjugated or nonspecific aga-
rose beads (Sigma-Aldrich). The following day, SF samples
were centrifuged to pellet the lectin glycoprotein complex, and
depleted SF supernatants were collected. Depletion of (1,2)-
linked fucosylated proteins was confirmed by lectin blotting.
ELISAs for MCP-1/CCL2 and RANTES/CCL5. ELISAs
were performed as previously described (23). To determine
(1,2)-linked fucosylated MCP-1/CCL2 and total MCP-1/
CCL2 in RA SF samples, we measured MCP-1/CCL2 from
sham-depleted and (1,2)-linked fucosylated protein–depleted
SF samples by using UEA-I–conjugated agarose beads. We
quantitated (1,2)-linked fucosylated MCP-1/CCL2 in SF sam-
ples by measuring total MCP-1/CCL2 in SF samples that were
either sham depleted or depleted of (1,2)-linked fucosylated
proteins with UEA-I–conjugated agarose beads, as described
above. Differences in the values of the sham-depleted and
(1,2)-linked fucosylated protein–depleted SF samples gave
the value of (1,2)-linked fucosylated MCP-1/CCL2 in SF
samples. Levels of MCP-1/CCL2 and RANTES/CCL5 in
TNF-stimulated or IL-1–stimulated HMVEC-conditioned
medium were measured according to the recommendations
of the manufacturer (R&D Systems). Levels of MCP-1/CCL2
and RANTES/CCL5 in TNF-stimulated or IL-1–stimulated
mouse lung EC–conditioned medium were measured by per-
sonnel at the University of Michigan Cancer Center Immunol-
ogy Core or using ELISA kits from commercial sources (R&D
Systems).
In vitro HMVEC chemotaxis assay. Chemotaxis assays
were performed using a 48-well modified Boyden chamber
system as previously described (23,27). To examine the bioac-
tivity of (1,2)-linked fucosylated proteins in RA SF samples,
we performed HMVEC chemotaxis assays using (1,2)-linked
fucosylated protein–depleted or sham-depleted RA SF sam-
ples. Each test group was assayed in quadruplicate. Three
high-power (400) fields were counted in each replicate well,
and results were expressed as cells per high-power field (hpf).
In vitro Matrigel tube formation assay. Matrigel tube
formation assays using growth factor–reduced Matrigel (BD
Biosciences) were performed (28,29). To examine the bioac-
tivity of (1,2)-linked fucosylated proteins in RA SF samples,
we performed HMVEC tube formation assays using (1,2)-
linked fucosylated protein–depleted or sham-depleted RA SF
samples. The controls used were vascular endothelial cell
growth factor (VEGF) (10 nM; R&D Systems) as a positive
control and PBS as a negative control. HMVECs (1.8  104
cells/400 l) were plated on Matrigel in the presence of 150
g/ml sham-depleted or (1,2)-linked fucosylated protein–
depleted RA SF for 6 hours at 37°C. Photographs (100) were
obtained, and tubes were counted in a blinded manner. Tubes
were defined as elongated connecting branches between two
identifiable HMVECs.
After finding that FUT1 plays an important role in
TNF-induced MCP-1/CCL2 and RANTES/CCL5 secretion,
we examined whether MCP-1/CCL2 and RANTES/CCL5 were
involved in TNF-mediated tube formation. We performed
HMVEC tube formation assays using TNF as a stimulus in
the presence or absence of neutralizing antibodies against
MCP-1/CCL2 and RANTES/CCL5 (R&D Systems).
Oligonucleotide (ODN) transfection. HMVECs were
seeded in 6-well plates at 1  105 cells per well. ECs were
maintained in EC basal medium with 5% FBS. Upon 70%
confluency, 2 g/ml FUT1 sense or antisense ODNs and
TransIT-Oligo transfection reagent (Mirus) was mixed accord-
ing to the manufacturer’s instructions and overlaid on the cells.
Cells were incubated with the ODNs/TransIT-Oligo transfec-
tion reagent for 24 hours at 37°C. FUT1 sense and antisense
ODNs were purchased from Integrated DNA Technologies.
The following FUT1 sequences were used: for FUT1 sense
ODN, TTTCTTCCACCATCTCCGGGAA and for FUT1 an-
tisense ODN, CCTTCTCTCCAACTCTCCCA. The percent
knockdown of FUT1 expression was determined by quantita-
tive polymerase chain reaction (qPCR).
RNA extraction and qPCR. RNA extraction and qPCR
were performed as previously described (30). Total RNA was
isolated from HMVECs transfected with sense or antisense
ODNs directed against FUT1, using RNeasy Mini RNA
isolation kits in conjunction with QIAshredder, following the
recommendations of the manufacturer (Qiagen). Using this
technique, we routinely yield 40 ng/l of RNA from 1  105
cells. Following isolation, RNA (2 l) was quantified and
checked for purity using a spectrophotometer (NanoDrop
Technologies). FUT1 and -actin primer pairs were purchased
from Integrated DNA Technologies. The following primers
were used: for FUT1, forward 5-GTGCCCGTATCCAGAG-
TGAT-3 and reverse 5-AGGACCCAGGGGAGAGTAAA-
3; for -actin, forward 5-GCTAGGCAGCTCGTAGCTC-
T-3 and reverse 5-GCCATGTACGTTGCTATCCA-3. All
samples were run in duplicate and analyzed using Applied
Biosystems software (Life Technologies).
EC chemotaxis with FUT1 gene–deficient and wild-
type mouse lung ECs. Mouse lung ECs (from passages 2–4)
were maintained in EC basal medium (Lonza) and 5% FBS.
For the assay, the cells were fed one night before with EC basal
medium with 5% FBS, harvested, and resuspended at 5  105
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cells/ml in EC basal medium with 0.1% FBS. EC chemotaxis
assays were performed using gelatin-coated polycarbonate
membranes (8 m pore size) (28,29). The chambers were
inverted and incubated for 2 hours to allow mouse EC
attachment. The chambers were reinverted, test substances
were added, and incubation was continued for 1 additional
hour. VEGF (Life Technologies) was used as a stimulus, and
PBS was used as a negative control.
HMVEC chemotaxis assay with FUT1 sense or anti-
sense ODN–transfected EC–conditioned medium. To further
examine the role of FUT1 in ECs, we performed HMVEC
chemotaxis assays using FUT1 sense or antisense ODN-
transfected HMVEC-conditioned medium to determine
whether HMVEC FUT1 inhibition alters the secretion of
chemotactic substances by cultured ECs. We used PBS as a
negative control and VEGF (10 nM; R&D Systems) as a
positive control for these studies.
Cell lysis and immunoblotting with mouse lung ECs.
Cell lysis and immunoblotting were performed as previously
described (29). Wild-type and FUT1 gene–deficient mouse
lung ECs were stimulated with TNF (25 ng/ml) for various
time periods. At the end of each time period, cell lysates were
prepared. The protein concentration in all of the samples was
measured with a bicinchoninic acid protein assay kit (Pierce).
Protein lysates (10 g) were run on 10% sodium dodecyl
sulfate–polyacrylamide gels and transblotted onto nitrocellu-
lose membranes (Bio-Rad). Blots were probed for rabbit
anti-mouse antibodies for various VEGF receptors
(VEGFRs). Blots were stripped and reprobed with -actin to
verify equal loading of proteins.
Statistical analysis. Data were analyzed using Stu-
dent’s t-test, assuming equal variances. Data are reported as
the mean  SEM. P values less than 0.05 were considered
significant.
RESULTS
Expression of (1,2)-linked fucosylated proteins
on RA ST endothelial cells. We examined the expression
of (1,2)-linked fucosylated proteins in RA, OA, and
normal ST samples. We used UEA-I and antibody to
UEA-I for immunohistology, because UEA-I binds spe-
cifically to (1,2)-fucose (31). We found that (1,2)-
linked fucosylated proteins were expressed on ST ECs
(Figure 1A). In addition, (1,2)-linked fucosylated pro-
teins were highly expressed in RA ST compared to
normal ST (mean  SEM percent (1,2)-linked fucosy-
lated protein–positive tubes of total tubes 60  6%
versus 32  9%; P  0.05) (Figure 1B). These results
suggest that (1,2)-linked fucosylation may be important
for EC angiogenic activity in RA ST.
Expression of (1,2)-linked fucosylated chemo-
kines in RA SF. We and others have shown chemokines
to be important in RA (32–34). To determine if (1,2)-
linked fucosylated chemokines were present in RA, we
performed (1,2)-linked fucosylated MCP-1/CCL2 im-
munoprecipitation studies. Figure 2A shows (1,2)-
linked fucosylated MCP-1/CCL2 in RA and OA SF. We
found that the expression of (1,2)-linked fucosylated
MCP-1/CCL2 was significantly elevated in RA SF com-
pared to OA SF (Figure 2B). In order to measure
Figure 1. Expression of (1,2)-linked fucosylated proteins in rheuma-
toid arthritis (RA), osteoarthritis (OA), and normal (NL) synovial
tissue (ST) endothelial cells (ECs). A, ST staining with Ulex europaeus
agglutinin type I (UEA-I) and goat anti–UEA-I antibody (Ab) (left),
staining with rabbit anti–von Willebrand factor (anti-vWF) antibody
(middle), and merge of the anti–UEA-I and anti-vWF stainings (right).
Yellow indicates (1,2)-linked fucosylated proteins associated with ST
ECs. Arrows indicate (1,2)-linked fucosylated protein–positive ECs.
Original magnification  200. B, Percentages of (1,2)-linked fucosy-
lated protein–positive vessels in RA, OA, and normal ST, determined
by counting the total number of yellow vessels and dividing that value
by the total number of vWF-positive vessels (green) in each tissue
section. RA ST had significantly higher percentages of (1,2)-linked
fucosylated protein–containing vessels compared to normal ST. IgG
control staining for all 3 groups did not show staining (results not
shown). Bars show the mean  SEM. The n values are the number of
patients.
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(1,2)-linked fucosylated MCP-1/CCL2 in RA SF, SF
samples were depleted of (1,2)-linked fucosylated pro-
teins using UEA-I–conjugated agarose beads. We then
determined whether (1,2)-linked fucosylated proteins
were depleted in SF by lectin blotting. We confirmed
that the expression of (1,2)-linked fucosylated proteins
was decreased after depletion (Figure 2C). We then
measured MCP-1/CCL2 by ELISA. The mean  SEM
values for (1,2)-linked fucosylated MCP-1/CCL2 and
total MCP-1/CCL2 in RA SF were 1.4  1.0 ng/ml and
2.1  1.2 ng/ml, respectively (n  10 patients) (Figure
2D). The percent of (1,2)-linked fucosylated MCP-1/
CCL2 of total MCP-1/CCL2 was 76  9% (n  10
patients). These results indicate that (1,2)-linked fuco-
sylated MCP-1/CCL2 is found in SF and is up-regulated
in RA SF compared to OA SF.
Function of (1,2)-linked fucosylated proteins in
RA SF. In order to demonstrate the function of (1,2)-
linked fucosylated proteins in RA SF, SF samples neu-
tralized of (1,2)-linked fucosylated proteins were as-
sayed for the ability to induce HMVEC chemotaxis and
tube formation. Because EC chemotaxis is an initial
step in the angiogenic process, we performed in vitro
HMVEC chemotaxis assays using sham-depleted or
(1,2)-linked fucosylated protein–depleted RA SF. We
found that (1,2)-linked fucosylated protein–depleted
RA SF samples (n  4 patients) showed a 54  2%
decrease in EC migratory activity compared to sham-
depleted controls (mean  SEM number of HMVECs
migrated 8  1 versus 17  2; P  0.05) (Figure 3A). In
addition, (1,2)-linked fucosylated protein–depleted
RA SF samples (n  4 patients) showed a 50  21%
decrease in EC tube-forming activity compared to sham-
depleted controls (mean  SEM number of HMVEC
tubes formed 6 2 versus 12 1; P 0.05) (Figure 3B).
Figure 3C shows a representative image of Matri-
gel in vitro. The total length of the tubes formed and the
number of nodes formed showed a similar trend. There
was a 72  7% decrease in total length of the tubes
formed in (1,2)-linked fucosylated protein–depleted
RA SF samples compared to sham-depleted controls
(mean SEM length 21 6 mm versus 71 4 mm; P
0.05) (results not shown). There was a 75  13%
decrease in the number of nodes in (1,2)-linked fuco-
sylated protein–depleted RA SF samples compared to
sham-depleted controls (mean  SEM 2  1 versus 6 
0; P  0.05) (Figure 3C). These findings suggest that
(1,2)-linked fucosylated proteins in RA SF have more
potent EC angiogenic activity compared to non–(1,2)-
linked fucosylated proteins. After finding that the pro-
duction of MCP-1/CCL2 was decreased in FUT1 gene–
deficient mouse lung ECs compared to wild-type mouse
lung ECs, we examined if MCP-1/CCL2 was involved in
TNF-mediated tube formation in HMVECs. We found
Figure 2. Expression of (1,2)-linked fucosylated monocyte chemoat-
tractant protein 1 (MCP-1)/CCL2 in synovial fluid (SF). A, Detection
of (1,2)-linked fucosylated MCP-1/CCL2 in SF samples from 6 RA
patients and 6 OA patients, by immunoprecipitation and lectin blot-
ting. B, Levels of (1,2)-linked fucosylated MCP-1/CCL2 in RA SF
and OA SF. There was a significant elevation of (1,2)-linked fucosy-
lated MCP-1/CCL2 in RA SF. Data were normalized to total MCP-1/
CCL2 and are the ratio of the densitometry of (1,2)-linked fucosy-
lated MCP-1/CCL2 to total MCP-1/CCL2 shown in A. The n values are
the number of patients. C, Left, Depletion of (1,2)-linked fucosylated
proteins in RA SF using UEA-I–conjugated agarose beads, as shown
by lectin blotting. Right, Coomassie brilliant blue staining. The (1,2)-
linked fucosylated proteins are decreased after depletion. D, Levels of
MCP-1/CCL2 in sham-depleted and (1,2)-linked fucosylated protein–
depleted RA SF, as measured using an MCP-1/CCL2 enzyme-linked
immunosorbent assay. The mean  SEM percent (1,2)-linked fuco-
sylated MCP-1/CCL2 of total MCP-1/CCL2 was 76  9%. Bars in B
and D show the mean  SEM. See Figure 1 for other definitions.
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Figure 3. Chemotactic and tube formation activity of (1,2)-linked fucosylated proteins in rheumatoid arthritis (RA) synovial fluid (SF). A, Number
of migrated human dermal microvascular endothelial cells (HMVECs) in sham-depleted and (1,2)-linked fucosylated protein–depleted RA SF.
HMVEC migration was measured using a chemotaxis assay. Depletion of (1,2)-linked fucosylated protein resulted in a mean  SEM 54  2%
reduction in RA SF–induced HMVEC migration. B, Number of tubes formed in sham-depleted and (1,2)-linked fucosylated protein–depleted RA
SF. There was less HMVEC tube-forming activity in (1,2)-linked fucosylated protein–depleted RA SF. C, HMVEC tubes formed by sham-depleted
and (1,2)-linked fucosylated protein–depleted RA SF. Arrows indicate tubes. Original magnification  100. D and E, Inhibition of tumor necrosis
factor  (TNF)–mediated HMVEC tube formation on Matrigel by blocking antibody against monocyte chemoattractant protein 1 (MCP-1)/CCL2.
Arrows indicate the number of tubes formed. Original magnification  40 in D. Bars in A, B, and E show the mean  SEM. The n values in A and
B are the number of patients; the n values in E are the number of replicates.
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that TNF-induced HMVEC tube formation was signif-
icantly decreased in the presence of neutralizing anti-
body to MCP-1/CCL2, suggesting that MCP-1/CCL2 is
involved, in part, in TNF-stimulated angiogenesis (Fig-
ures 3D and E). We did not see a similar effect with
RANTES, suggesting that this chemokine is regulated
differently than MCP-1/CCL2 in this system (data not
shown).
Validation of the purity of the mouse lung ECs
by flow cytometry. To validate the purity of the EC
population, flow cytometry was performed using FITC-
conjugated CD146, a mouse EC marker. ECs were 76%
CD146 positive (Figure 4A).
Decreased EC chemotaxis in FUT1 gene–
deficient mouse lung ECs versus wild-type ECs. To
determine the role of FUT1 in angiogenesis, we per-
formed in vitro chemotaxis assays. FUT1 gene–deficient
and wild-type mouse lung ECs were assayed for their
chemotactic response to VEGF, in a modified Boyden
chamber. We found that FUT1 gene–deficient mouse
lung ECs showed decreased migration toward VEGF
compared to wild-type mouse lung ECs (mean  SEM
Figure 4. A, Purity of wild-type mouse lung endothelial cells (MLECs), as determined by flow cytometry. The purity of C57BL/6 wild-type (WT)
mouse lung ECs was 76.3%, as determined by CD146 staining via flow cytometric analysis. Blocking fucosyltransferase 1 (FUT1) in ECs reduced
EC chemotaxis. Green represents CD146-positive cells; black represents control IgG. Results are representative of 2 independent assays. B,
Reduction in cell migration in ECs completely lacking FUT1 expression. FUT1 gene–deficient mouse lung ECs had significantly less migration
compared to wild-type mouse lung ECs in response to mouse vascular endothelial cell growth factor (VEGF; 10 nM and 100 nM). hpfs high-power
fields. The n value is the number of experiments. C, Marked increase in Flt1/VEGF receptor 1 (VEGFR1) induced by tumor necrosis factor 
(TNF; 25 ng/ml) in wild-type mouse lung ECs compared to FUT1 gene–deficient mouse lung ECs at 8, 16, and 24 hours. Results are representative
of 2 independent assays. KDR  kinase insert domain receptor. D, FUT1 antisense oligonucleotide (ODN)–transfected HMVEC–conditioned
medium reduces HMVEC migration compared to FUT1 sense ODN–transfected HMVEC–conditioned medium. Phosphate buffered saline (PBS)
and VEGF were used as negative and positive controls, respectively. The mean  SEM number of HMVECs migrating toward PBS was 5  1 and
the number migrating toward VEGF was 40 6. Bars show the mean SEM. The n value is the number of experiments. Color figure can be viewed
in the online issue which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38648/abstract.
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number of mouse lung ECs migrated 10 1 versus 16
1 at 10 nM [n  6] and 8  1 versus 14  2 at 100 nM
[n 6]; P 0.05) (Figure 4B). After finding that VEGF
induces migration of mouse lung ECs, we examined the
expression of angiogenic VEGFRs in FUT1 gene–
deficient and wild-type mouse lung ECs. We found that
Flt1/VEGFR-1 levels were markedly increased in a
time-dependent manner in wild-type mouse lung ECs
stimulated with TNF compared to FUT1 gene–
deficient mouse lung ECs stimulated with TNF. This
suggests a mechanism by which FUT1 gene–deficient
mouse lung ECs migrate less in response to VEGF
(Figure 4C). However, we did not find a decrease in
levels of kinase insert domain receptor/VEGFR-2, an-
other receptor for VEGF, in response to TNF in FUT1
gene–deficient mouse lung ECs compared to wild-type
mouse lung ECs (Figure 4C).
Reduction in EC migration to conditioned me-
dium upon blocking of FUT1 expression in ECs. To
further examine the function of FUT1 in ECs, we used
HMVECs transfected with sense or antisense ODNs
directed against FUT1. The mean  SEM percent
knockdown of FUT1 in antisense ODN–transfected
HMVECs was 41  7% (n  3). We performed
HMVEC chemotaxis toward FUT1 sense ODN– or
antisense ODN–transfected HMVEC–conditioned me-
Figure 5. Reduction in expression of proangiogenic chemokines by blocking FUT1 expression in ECs. Cells were treated with interleukin-1
(IL-1) for 72 hours, and conditioned medium was assayed. A, Levels of monocyte chemoattractant protein 1 (MCP-1)/CCL2 in human dermal
microvascular endothelial cell (HMVEC)–conditioned medium transfected with FUT1 sense (S) ODN or FUT1 antisense (AS) ODN and stimulated
with IL-1. There was a mean  SEM 21  3% decrease in MCP-1/CCL levels in HMVEC-conditioned medium transfected with FUT1 antisense
ODN. B, Levels of RANTES/CCL5 in HMVEC-conditioned medium transfected with FUT1 sense ODN or FUT1 antisense ODN and stimulated
with IL-1. There was a mean  SEM 41  0% decrease in RANTES/CCL5 levels in HMVEC-conditioned medium transfected with FUT1
antisense ODN. C, Levels of MCP-1/CCL2 in wild-type and FUT1 gene–deficient mouse lung EC–conditioned medium stimulated with IL-1.
There was a mean  SEM 15  5% decrease in MCP-1/CCL2 levels in FUT1 gene–deficient mouse lung EC–conditioned medium. D, Levels of
RANTES/CCL5 in wild-type and FUT1 gene–deficient mouse lung EC–conditioned medium stimulated with IL-1. There was a mean SEM 59
1% decrease in RANTES/CCL5 levels in FUT1 gene–deficient mouse lung EC–conditioned medium. E, MCP-1/CCL2 expression induced by tumor
necrosis factor  (TNF) in FUT1 gene–deficient and wild-type mouse lung ECs after 16 and 24 hours. TNF expression was significantly lower
in FUT1 gene–deficient mice at both time points. Bars show the mean  SEM. The n values are the number of replicates. See Figure 4 for other
definitions.
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dium and found that FUT1 antisense ODN–transfected
HMVEC–conditioned medium showed a significant de-
crease in the chemotactic activity of HMVECs com-
pared to FUT1 sense ODN–transfected HMVEC–
conditioned medium (mean  SEM number of
HMVECs migrated 7  1 versus 17  2; P  0.05)
(Figure 4D).
Reduction in expression of proangiogenic chemo-
kines upon blocking of FUT1 expression in ECs. To
determine whether angiogenic chemokines were present
in EC-conditioned medium and whether their expres-
sion was regulated by proinflammatory cytokines, ELI-
SAs were performed on conditioned medium. HMVECs
were transfected with FUT1 antisense ODNs and then
stimulated with IL-1 to induce chemokine production.
This conditioned medium contained much lower levels
of MCP-1/CCL2 than medium from sense-transfected
HMVECs when stimulated with IL-1 (Figure 5A).
(The mean  SEM level of MCP-1/CCL2 was 1,578 
35 pg/ml for unstimulated medium transfected with
FUT1 sense ODN versus 343  30 pg/ml for unstimu-
lated medium transfected with FUT1 antisense ODN;
n  4 replicates.) RANTES/CCL5 levels were also
decreased in response to IL-1 in FUT1 antisense
ODN–transfected HMVEC–conditioned medium com-
pared to FUT1 sense ODN–transfected HMVEC–
conditioned medium (Figure 5B). (The mean  SEM
level of RANTES/CCL5 was 51  2 pg/ml for unstimu-
lated medium transfected with FUT1 sense ODN versus
44  4 pg/ml for unstimulated medium transfected with
FUT1 antisense ODN; n  4 replicates.) (Figure 5B).
We also found that MCP-1/CCL2 levels were
significantly decreased in IL-1–stimulated FUT1 gene–
deficient mouse lung EC conditioned medium compared
to wild-type mouse lung EC conditioned medium (Fig-
ure 5C). (The mean  SEM level of MCP-1/CCL2 was
316  28 pg/ml for unstimulated wild-type mouse lung
EC conditioned medium versus 302  79 pg/ml for
unstimulated FUT1 gene–deficient mouse lung EC con-
ditioned medium; n  4 replicates.) RANTES/CCL5
levels were also significantly decreased in FUT1 gene–
deficient mouse lung EC conditioned medium compared
to wild-type mouse lung EC–conditioned medium in
response to IL-1 (Figure 5D). (The mean  SEM level
of RANTES/CCL5 was 85  22 pg/ml for unstimulated
wild-type mouse lung EC–conditioned medium versus
9  5 pg/ml for unstimulated FUT1 gene–deficient
mouse lung EC–conditioned medium; n  4 replicates.)
However, expression of MCP-1/CCL2 and RANTES/
CCL5 was not significantly decreased in conditioned
medium when TNF was used as a stimulus with similar
culture conditions (data not shown). We also measured
VEGF in FUT1 gene–deficient and wild-type mouse
lung EC–conditioned medium, and did not find signifi-
cant differences between FUT1 gene–deficient and wild-
type mouse lung EC–conditioned medium (data not
shown). These findings indicate that FUT1 inhibition
can regulate CC chemokine production in ECs.
To examine the possibility that peak chemokine
induction stimulated with TNF may occur at a time
point earlier than 24 hours, we measured the expression
of MCP-1/CCL2 in conditioned media collected from
FUT1 gene–deficient mouse lung ECs and wild-type
mouse lung ECs stimulated with TNF at 16 and 24
hours. TNF induced significantly higher MCP-1/CCL2
secretion in wild-type mouse lung ECs compared to
FUT1 gene–deficient mouse lung ECs at both 16 and 24
hours (Figure 5E). However, we did not see this differ-
ence at 8 hours (data not shown).
DISCUSSION
Glycosylation is involved in various events such as
cell growth, cell migration, and tumor invasion. Approx-
imately 50% of all proteins are glycosylated (35), sug-
gesting that glycosylation is critical for proper protein
function. Interestingly, it has also been shown that
dysregulated protein glycosylation can lead to enhanced
pathologic responses. For example, oligosaccharides on
glycoproteins are altered during tumorigenesis, and play
a role in regulating the metastatic potential of tumor
cells (36).
Alpha-fetoprotein and prostate-specific antigen
are commonly used tumor markers. However, elevated
levels of these markers occur not only in cancer but also
in benign diseases, whereas some groups reported that
fucosylated tumor markers were more specific markers
for active disease (6,37). The present study demonstrates
that (1,2)-linked fucosylated proteins are expressed in
RA, and that the levels are highly elevated compared to
levels in normal ST. We also show that (1,2)-linked
fucosylated MCP-1/CCL2 is present in RA SF, and that
the levels are significantly elevated compared to levels in
OA SF. Przybysz et al reported that the fucosylation of
fibronectin in SF and blood plasma were related to RA
progression (38). Ferens-Sieczkowska et al noted that
fucosylation of synovial glycoconjugates could be a reli-
able clinical marker for RA and juvenile idiopathic
arthritis (JIA) (39). All fucosylated proteins in RA, JIA,
and traumatized knee SF samples were detected with
Aleuria aurantia, one of the fucose-specific lectins. Fu-
cosylated protein levels in RA and JIA were also ele-
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vated compared to those in traumatized knee SF. How-
ever, no one has shown the role of fucosylation in RA.
Our findings support the notion that (1,2)-linked fuco-
sylation is important in RA pathogenesis.
We examined the (1,2)-linked fucosylation of
MCP-1/CCL2 because this chemokine is an important
monocyte chemotactic factor in RA and an angiogenic
factor (32,33,40). We measured (1,2)-linked fucosy-
lated MCP-1/CCL2 using UEA-I–conjugated agarose
beads, and found that the percent of (1,2)-linked
fucosylated MCP-1/CCL2 of total MCP-1/CCL2 in
RA SF was 76  9%. Our finding of elevated levels of
(1,2)-linked fucosylated MCP-1/CCL2 in RA SF sug-
gests that posttranslational modification of this chemo-
kine is increased in inflammatory environments such as
the RA joint.
We previously found that FUT1 is expressed in
the synovial lining of RA ST (41), and that (1,2)-linked
fucosylated proteins were overexpressed in RA. Because
of this, we sought to determine whether these proteins in
RA SF had chemotactic and angiogenic activity. We
found that RA SF depleted of (1,2)-linked fucosylated
proteins induced less HMVEC migration compared to
sham-depleted RA SF, suggesting that (1,2)-linked
fucosylation may have an important function in RA
angiogenesis. Interestingly, Proost et al reported that
glycosylated MCP-1/CCL2 was 2–3-fold less chemotactic
for monocytes and THP-1 cells than nonglycosylated
MCP-1/CCL2 (42). This discrepancy might be explained
by the fact that they examined different cells and studied
total glycosylation of MCP-1/CCL2, whereas we exam-
ined only (1,2)-linked fucosylation. Carlyon et al re-
ported that FUT4 gene– and FUT7 gene–deficient
mouse neutrophils exhibited decreased secretion of the
chemokines macrophage inflammatory protein
2/CXCL2 and keratinocyte-derived chemokine com-
pared to wild-type mouse neutrophils (43). However,
production of angiogenic chemokines in FUT1 gene–
deficient ECs has not been demonstrated.
Mathieu et al reported that tumor vascularization
was decreased after FUT1 inhibition (44), and sup-
ported the findings of Palumberi et al, who showed that
adhesion of human epidermoid carcinoma cells to FUT1
and FUT2 small interfering RNA (siRNA)–transfected
ECs was decreased compared to control siRNA–
transfected ECs. These investigators also reported that
FUT1 and FUT2 siRNA–treated human epidermoid
carcinoma cells have reduced cell proliferation when
transfected with FUT1 or FUT2 siRNA (45). We have
previously shown that, compared to wild-type mouse
lung ECs, FUT2 gene–deficient mouse lung ECs have
less chemotactic activity toward basic fibroblast growth
factor, and that FUT2 gene–deficient mouse lung ECs
have lower fibroblast growth factor receptor 2 expres-
sion (46). In this study, we found that mouse lung ECs
isolated from FUT1 gene–deficient mice had decreased
migration toward VEGF compared to wild-type mouse
lung ECs, indicating that FUT1 plays an important role
in EC chemotaxis. We also found that FUT1 antisense
ODN–transfected HMVEC–conditioned medium had
less HMVEC chemotactic activity than FUT1 sense
ODN–transfected HMVEC–conditioned medium. This
result indicates that FUT1 affects EC migration not only
directly but also indirectly, as it appears that angiogenic
factors may be secreted from HMVECs, mediated by
FUT1 expression.
MCP-1/CCL2 and RANTES/CCL5 are well-
known chemokines that induce angiogenesis and leuko-
cyte recruitment (34,40). We found that MCP-1/CCL2
and RANTES/CCL5 secretion was up-regulated in
HMVECs by IL-1. We also found that MCP-1/CCL2
and RANTES/CCL5 levels were decreased in IL-1–
stimulated FUT1 gene–deficient mouse lung EC–
conditioned medium compared to similarly treated
control–conditioned medium. These findings point to
FUT1 as a critical intermediary in expression of some
angiogenic chemokines known to be important in RA
pathogenesis.
In summary, our study demonstrated that (1,2)-
linked fucosylated proteins are expressed on RA ST
endothelial cells, and that (1,2)-linked fucosylated pro-
teins in RA SF have angiogenic ability. We also found
that (1,2)-linked fucosylated MCP-1/CCL2 was present
in RA SF, and that the level of (1,2)-linked fucosylated
MCP-1/CCL2 was significantly elevated in RA SF com-
pared to OA SF. Finally, we showed that blocking FUT1
in ECs reduced CC chemokine production and EC
migration. Taken together, these results demonstrate
the importance of (1,2)-linked fucosylation by FUT1 in
RA angiogenesis.
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